Dr. Trougakos has received post‐doctoral fellowships from the EU and the Scholarship Foundation of the Hellenic State; has participated in many international practical courses (EMBO, FEBS), has been honoured with various awards and he was an invited lecturer in international conferences. He teaches in post‐graduate M.Sc. or Ph.D. courses at the Faculty of Biology and the Medical School of NKUA, he is a member of several Scientific Societies; has participated as a senior researcher in several EU research projects; serves as a reviewer in numerous international journals and he is an Editorial Board member of “Journal of Ageing Research” and “Biogerontology”. Dr Trougakos was a member of the Scientific Committee for the “12th Congress of the International Association of Biomedical Gerontology (IABG)”, co‐organized the “5th Workshop on Apolipoprotein J/Clusterin” and was appointed reviewer for the “8th IEEE International Conference on Bioinformatics and Bioengineering (BIBE)”. He was Associate member of the EU Grant “Link‐Age”, while currently he serves as national representative and member of the Management Committee of the EU COST Actions “Cancer and Control of Genomic Integrity”, and “Synthetic Probes for Chemical Proteomics and Elucidation of Biosynthetic Pathways”. He is also a nominated member of the Management Committee of the EU COST Action “Chemistry of non‐enzymatic protein modification – modulation of protein structure and function”. Dr Trougakos was invited to participate in panels of the “WhyWeAge ‐ A road map for molecular Biogerontology” EU project; has been honoured with research grants and he is Deputy Coordinator of the EU grant “INsPiRE” (2011‐2014, FP7 programme CAPACITIES‐REGPOT). He has published several articles in high‐ranking journals, chapters in
international books and he co‐authors an academic book. Finally, a link with RTD performers or SMEs has been established following the presentation of two patents related to an Apolipoprotein J/Clusterin ELISA method and the development of RNAi probes targeting cancer related genes.